RxDoctor Payments Data

Curtis Kodama, DO

Family Medicine · Moorpark, CANPI 1679560973

Payments from drug & device makers

$1,918in general payments, 2019–2025

Across 97 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$480
  • Amgen$430
  • Takeda Pharmaceuticals U.S.A., Inc.$316
  • Lilly USA, LLC$175
  • Novo Nordisk$85
  • Intuitive Surgical$78
  • plus $354 from 10 others

What the payments were for

  • Food & beverage$1,918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,918 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$182,036
Medicare patients
622
Services billed
2,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide146$186,465
JardianceEmpagliflozin50$62,031
JanuviaSitagliptin Phosphate42$43,196
EliquisApixaban44$40,968
TrulicityDulaglutide34$40,651
FarxigaDapagliflozin Propanediol33$36,802
MounjaroTirzepatide27$27,338
TradjentaLinagliptin13$19,455
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$18,850
XareltoRivaroxaban21$18,668
JanumetSitagliptin Phos/Metformin Hcl20$18,333
MyrbetriqMirabegron12$14,291
Tresiba Flextouch U-200Insulin Degludec14$11,565
LinzessLinaclotide15$10,034
Tresiba Flextouch U-100Insulin Degludec17$9,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$85$186,465146 claims
Boehringer IngelheimJardiance, Tradjenta$47$81,48663 claims
Lilly USA, LLCTrulicity, Mounjaro$175$67,98961 claims
MerckJanuvia, Janumet$12$61,52962 claims
PfizerEliquis, Paxlovid$46$43,71670 claims
AstraZenecaFarxiga$41$36,80233 claims
AbbVieLinzess$480$10,03415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Moorpark

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →